Additionally, exploring the levels of EGFR, PD‐L1, and TMEM16A in early‐stage HNSCC is vital to confirm the viability of the targeted therapy proposed in this review for use in the early stages of this disease. The gene discussed is ANO1; the disease is head and neck squamous cell carcinoma.